News

The U.S. Food and Drug Administration (FDA) has given Pheno Therapeutics the green light to begin clinical testing of PTD802, the company’s oral lead treatment candidate for boosting myelin repair in people with multiple sclerosis (MS) and other neurological diseases. The experimental remyelination therapy aims to potentially…

Taking high-dose vitamin D supplements for more than a year can significantly cut relapse risks and ease disability for people with multiple sclerosis (MS), according to a comprehensive review of more than 30 clinical trials. These benefits were observed in patients who added the vitamin to their standard…

Computer-based analyses of microorganisms in the digestive tract can distinguish people with multiple sclerosis (MS) from healthy individuals with high accuracy, according to a new study. The analysis looked beyond gut bacteria to include other organisms like fungi and viruses. The findings suggest these comprehensive microbial profiles could eventually…

Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previous two years. The medication will be sold under the brand name Cenrifki. The decision, which is in line with a…

People who develop multiple sclerosis (MS) at age 50 or later are more likely to accumulate disability through mechanisms that are not directly linked to relapses or MRI activity than those with earlier-onset disease, according to an Italian registry study. “This suggests that the adverse prognostic effect of [late-onset…

Despite being converted into the same active ingredient, the newer multiple sclerosis (MS) drug Vumerity (diroximel fumarate) is associated with significantly lower relapse rates than the older medication Tecfidera (dimethyl fumarate), or its generics, in people with relapsing forms of MS. Those are the findings of a…

An international trial will test a combined approach to targeting underrecognized cognitive symptoms of multiple sclerosis (MS), coaching patients on becoming more conscientious with the aim of making them more likely to stick with treatment plans. Difficulties with learning, memory, and related functions are among the symptoms of MS, affecting…

Scientists have identified six proteins that could serve as targets for new treatments designed to slow multiple sclerosis (MS) progression. The data showed that one protein, RRM2B, may interact with the approved MS treatment Mavenclad (cladribine), while the other proteins interacted with molecules that are not currently used…

People with multiple sclerosis (MS) who were older than 60 had a low risk of disease flares whether they continued or stopped taking disease-modifying therapies (DMTs), according to a recent study. According to researchers, these data suggest that some older adults with MS may be able to consider…

For teenagers, eating a healthy diet during one’s adolescent years — particularly one rich in milk, cheese, and yogurt, among other dairy products — may help reduce the risk of developing late-onset multiple sclerosis (MS) later in life, a study has found. In fact, participants in the study who…

An autologous hematopoietic stem cell transplant (aHSCT) helped over 80% of people with multiple sclerosis (MS) remain free from disease activity for at least two years, a real-world study in Germany found. The strongest benefits were seen in people with relapsing-remitting MS (RRMS), with better outcomes observed in…

Two new research projects are looking at whether the hormonal and biological changes that happen around menopause play a role in how multiple sclerosis (MS) progresses in women, which could help doctors better predict the course of the disease and time treatments more effectively. “By better understanding the biological…

An artificial intelligence (AI) model that analyzes brain scans alongside clinical and demographic data showed high accuracy in predicting which people with multiple sclerosis (MS) were likely to experience cognitive decline over time, according to a new study. Using tools that show which parts of the data most influenced…

The number of people living with multiple sclerosis (MS) has risen steadily over the past two decades, but the increase appears to be driven largely by longer survival after diagnosis rather than by more people developing the disease. That’s according to findings of a large study that analyzed nationwide…

Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S. Food and Drug…

Among people with clinically isolated syndrome (CIS) — an initial episode of symptoms suggestive of multiple sclerosis (MS) — lower levels of certain fatty molecules in the blood are associated with higher rates of future disease relapses, a new study found. Adding these metabolic features to established demographic…

A new study in mice shows that an advanced imaging technique called magnetic particle imaging, or MPI, can track exactly where therapeutic cells go after they are injected into the body. This approach could eventually help researchers and doctors study and optimize cell-based therapies for people with multiple sclerosis…

The approved injection therapy Kesimpta (ofatumumab) is generally safe and helps most adults with relapsing forms of multiple sclerosis (MS) keep their disease stable over time with few or no relapses, a real-world study has found. The data show treatment is especially effective when started at a younger…

Differences in gut bacteria may affect how people with multiple sclerosis (MS) respond to dietary interventions, according to a study. The researchers stressed that their analysis was limited to data from a small group of people, so further studies will be needed to validate and expand on the results.

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Quantum Biopharma’s application seeking clearance to begin a Phase 2 trial testing Lucid-MS in people with multiple sclerosis (MS). Quantum said the FDA requested further information before clearing the investigational new drug (IND) application and…

A new formulation of Briumvi (ublituximab) — TG Therapeutics’ therapy for relapsing forms of multiple sclerosis (MS) — designed for possible at-home self-injection was generally well tolerated and showed biological activity consistent with the approved intravenous (into-the-vein) version, according to Phase 1 trial data. The Phase 1 trial is…

First-line treatment with TG Therapeutics’ Briumvi (ublituximab) in clinical trials among people with relapsing forms of multiple sclerosis (MS) led to significantly fewer relapses, reduced signs of MRI disease activity, and better disability outcomes compared with those given the older drug Aubagio (teriflunomide) as their initial therapy.

The Multiple Sclerosis Association of America (MSAA) is expanding its patient-centered research network to include more than 1,000 people with multiple sclerosis (MS) receiving care at 20 sites across the U.S. Known as the Multiple Sclerosis Implementation Network (MSIN), the initiative brings together healthcare providers, researchers, people…

Higher consumption of ultra-processed foods, such as soft drinks, packaged snacks, and ready-to-eat meals, may be associated with an increased risk of developing multiple sclerosis (MS). That’s according to a large study involving nearly 186,000 middle-aged adults in the U.K., which found that each 10% increase in ultra-processed food intake…

A new report from the National MS Society reveals that despite major advances in treatments over the last few decades, people living with multiple sclerosis (MS) still face massive gaps in their care — particularly when it comes to managing crushing fatigue, stopping disease progression, and reversing nerve…

Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely to achieve…

A new partnership aims to advance software that uses artificial intelligence (AI) to examine brain MRI scans for signs characteristic of multiple sclerosis (MS). Neurophet said it will work with the Vall d’Hebron Institut de Recerca (VHIR), the research institute of Vall d’Hebron University Hospital in Spain, to…

An app-based, one-to-one peer support program from Shift.ms that connects people newly diagnosed with multiple sclerosis (MS) with someone more experienced may help them feel more confident in managing their condition, with self-reported psychological benefits for both people in the pairing. That’s according to five-year data from the…

Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a study found. The findings also point to a possible therapeutic target. Researchers showed that blocking an enzyme called MAGL may help reverse…

Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global Phase…